EKTA-B
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

Elekta is a medical technology company that develops clinical products and software for the treatment of cancer and brain disorders. The company provides image-guided radiotherapy systems, stereotactic radiosurgery platforms, and MR-guided radiation therapy solutions, including the Elekta Evo and Elekta Unity Pro systems. Its portfolio also includes brachytherapy products and oncology information systems designed to optimize clinical workflows. Elekta serves radiation oncologists, neurosurgeons, and healthcare providers across three geographic regions: Americas, EMEA, and APAC. The company offers both product sales and service contracts, with a significant portion of revenue derived from service agreements tied to its installed base of equipment. Founded in 1972, Elekta operates globally and focuses on precision radiation therapy, adaptive treatment, and integrated care solutions.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Medical Devices Homepage elekta.com
Sector Healthcare IR page ir.elekta.com
Tags
radiotherapy, radiosurgery, oncology, adaptive treatment, brachytherapy, medical imaging, clinical software, precision medicine, Elekta Evo, Iris, Elekta ONE Online, Elekta Unity Pro, Leksell Gamma Knife, Elekta Care Learning
Press page elekta.com/company/newsroom/press-releases

Metrics

Valuation  
Market cap kr 19.677B
Market cap (USD) $ 1.946B
P/E 15.69
PEG 3.49
P/BV —
P/S 1.43
P/OCF 7.71
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.4%
ROI 11.2%
ROIC 17.0%
Profit margin 9.1%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 4.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 37.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score 31.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 13.763B 14.601B 13.555B 11.333B 10.704B 11.221B 10.839B 10.694B 10.339B 9.048B 7.904B 7.392B 7.392B
Net profit 1.254B 1.084B 1.198B 1.099B 125M 137M 552M 1.148B 1.34B 1.227B 1.031B 838M 838M

Figure FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price — 77.68 109.2 66.79 83.27 — — — — — — — —
Price performance 12m — -0.29 0.64 -0.2 — — — — — — — — —

Filed figures

Figure Apr 2020 Apr 2021 Apr 2022 Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (SEK) — 3.28B 3.65B 3.99B 3.88B 3.63B 3.69B
↳ YoY growth +11.2% +9.4% -2.8% -6.5% +1.7%
↳ 5y CAGR +2.4%
Other receivables (SEK) — 1.12B 1.48B 1.6B 1.54B 1.47B 1.21B
Borrowings, current (SEK) — 2.14B 510M 14M 1.12B 178M 2.94B
Borrowings, non-current (SEK) — 3.04B 4.1B 5.71B 4.81B 6.2B 3.38B
Lease liabilities (SEK) — 1.05B 1.09B 948M 1.32B 1.19B 1.01B
Cash and deposits (SEK) 6.41B 4.41B 3.08B 3.28B 2.78B 2.96B 3.19B
Right-of-use assets (SEK) — 953M 975M 773M 1.16B 1.01B 846M
Net debt (borrowings + leases - cash) (SEK) — 1.83B 2.62B 3.39B 4.47B 4.61B 4.14B
Cash flow detail
Operating cash flow (SEK) — 2.55B 1.86B 1.96B 2.46B 2.63B 2.46B
Purchases of property, plant and equipment (SEK) — -167M -188M -207M -252M -200M -120M
Purchases of intangible assets (SEK) — -678M -1.22B -1.36B -1.39B -1.37B -952M
Change in receivables (cash effect) (SEK) — -772M -291M -969M 313M -657M 756M
Change in inventories (cash effect) (SEK) — 270M -97M -461M -93M 325M -160M
Change in payables (cash effect) (SEK) — 393M 376M 1.28B -441M 128M 111M
Dividends paid (cash effect) (SEK) — -688M -841M -917M -917M -917M -917M
Interest paid (cash effect) (SEK) — -249M -156M -235M -366M -527M -390M
Income taxes paid (cash effect) (SEK) — -465M -452M -290M -431M -311M -379M
Operating cash flow before change in receivables (SEK) — 3.32B 2.15B 2.93B 2.15B 3.28B 1.71B
Free cash flow (OCF - PPE - intangibles) (SEK) — 1.71B 450M 400M 817M 1.06B 1.39B
Income detail
Research and development expense (SEK) — 1.49B 1.37B 1.42B 1.4B 2.68B 2.63B
↳ 5y CAGR +12.1%
Total comprehensive income (SEK) — 759M 1.54B 1.72B 1.94B -1.07B -781M
Comprehensive income to owners (SEK) — 760M 1.54B 1.71B 1.94B -1.07B -785M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

EN SV

Login

Elekta’s Nomination Committee for the Annual General Meeting 2027

October 30, 2026

STOCKHOLM – Elekta’s (EKTA-B.ST) Nomination Committee for the Annual General Meeting 2027 has been appointed in accordance with the instructions for the Nomination Committee adopted by the Annual General Meeting 2024.

The Nomination Committee consists of:

  • Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties’ holdings
  • Anna Magnusson, appointed by the Fourth Swedish National Pension Fund
  • Katarina Hammar, appointed by Nordea Funds
  • Robin Nestor, appointed by Lannebo Kapitalförvaltning
  • Monica Åsmyr, appointed by Swedbank Robur Funds

The Nomination Committee will appoint one of its members as Chairman.
  
Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail to [email protected] or by letter to:

Elekta AB (publ)
Att: Nomination Committee
P.O. Box 7593
SE-103 93 Stockholm
Sweden
 
In order for the Nomination Committee to be able to process any proposals constructively, these should be received by the Nomination Committee no later than June 4, 2027.
 
# # #
 

EN SV

Login

New phase 2 data show favorable cognitive outcomes with Leksell Gamma Knife in patients with up to 50 brain metastases

September 29, 2026

BOSTON – Elekta (EKTA-B.ST) today announced new phase 2 data, presented at ASTRO by lead investigator Dr. Chia-Lin Tseng, demonstrating favorable cognitive outcomes with Leksell Gamma Knife® radiosurgery in patients with up to 50 brain metastases. The study, conducted by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, evaluated focal stereotactic radiosurgery in patients with 5 to 50 brain metastases. The findings support a growing body of evidence that Gamma Knife radiosurgery may expand the use of focal treatment to patients with a higher number of brain metastases than traditionally considered.

The study used Gamma Knife radiosurgery together with Sunnybrook’s Spatially Partitioned Adaptive Radiosurgery technique, known as SPARE, an approach developed for patients with multiple brain metastases. Results showed favorable memory performance two months after treatment. Investigators also reported no difference in time to meaningful cognitive decline between patients with 21 to 50 metastases and those with 5 to 20 metastases.

Brain metastases are among the most common intracranial tumors, and as patients live longer with advanced disease, the need for precise and efficient treatment options continues to grow. Leksell Gamma Knife stereotactic radiosurgery is designed to treat visible tumors while limiting radiation exposure to surrounding healthy brain tissue, helping support the goal of preserving cognitive function and quality of life.

“Gamma Knife radiosurgery has long been associated with exceptional precision in the brain,” says John Christodouleas, MD, MPH, Head of Medical Affairs and Partner Research at Elekta. “These findings are important because they add to the clinical evidence supporting focal treatment approaches for patients with multiple brain metastases, including patients with higher numbers of metastases than have traditionally been treated with stereotactic radiosurgery.”

“We are encouraged by our findings showing SRS is associated with sustained memory performance at the two-month mark after treatment, despite treating up to 50 brain tumors in a single patient,” says Dr. Arjun Sahgal, senior author of the abstract and senior scientist with the Odette Cancer Research Program at Sunnybrook Research Institute. “While further comparative investigations are needed, the demonstration of sustained cognitive function suggests expansion of the indication to focally radiate patients with multiple metastases and avoid the harmful effects of whole brain radiation.”

According to the investigators, this is the first clinical trial to report outcomes for patients with up to 50 brain metastases treated with stereotactic radiosurgery. The findings support the continued evolution of Gamma Knife radiosurgery as a treatment approach for selected patients who may otherwise be considered for whole brain radiation, which can be associated with a risk of detrimental cognitive side effects.

# # #

EN SV

Login

Study presented at ASTRO shows promising long-term outcomes for patients with localized pancreatic cancer treated on Elekta Unity

September 28, 2026

New data underscore the potential of MR-guided adaptive radiotherapy as Elekta advances Elekta Unity with Unity Pro to help bring adaptive treatment to more centers.

BOSTON – Elekta (EKTA-B.ST) highlights new data presented at ASTRO 2026 showing unprecedented long-term survival outcomes for patients with localized pancreatic cancer treated with high-dose, adaptive radiotherapy on Elekta Unity MR-Linac. The study, conducted at Memorial Sloan Kettering Cancer Center in New York, U.S., followed patients who were not eligible for surgical resection, a group with a historically dismal prognosis.

Pancreatic cancer is difficult to treat, and many patients with localized disease cannot undergo surgery. For these patients, radiotherapy can be an important option, but treatment requires a high level of precision because the tumor may be close to healthy organs that shift between treatment sessions. Elekta Unity is designed to give care teams detailed MR imaging at the time of treatment, helping them adjust delivery based on the patient’s anatomy that day.

The study included 123 patients treated with MR-guided adaptive radiotherapy between May 2020 and December 2024 using Elekta Unity. Patients received treatment in five sessions over two weeks, with daily online adaptation used to help tailor treatment to the patient’s anatomy at each session.

After a median follow-up of just over two years, the study reported overall survival rates of 37.4 percent at two years and 26.3 percent at three years from radiotherapy. Local tumor control remained high, with 76.8 percent of patients free from local progression at both two and three years. These results are highly encouraging given the historically poor prognosis of localized pancreatic cancer.

“For patients with localized pancreatic cancer who are not candidates for surgery, while systemic treatment options are expanding, there is no option for long-term survival or cure with those treatments alone and the clinical need is significant. This is where ablative radiotherapy plays a major role” says Marsha Reyngold, MD, Memorial Sloan Kettering Cancer Center, and first author of the study. "Our approach using Elekta Unity to deliver high-dose ablative radiotherapy was associated with durable local control and very promising long-term survival outcomes, supporting further evaluation of this approach."

The research adds to ongoing evaluation of high-dose adaptive radiotherapy for selected patients with localized pancreatic cancer. It also points to the importance of technology that can help deliver precise, personalized treatment, accounting for the tumor’s position, nearby organs and the patient’s changing anatomy from day to day.

The findings come as Elekta continues to invest in Elekta Unity with Unity Pro, the next evolution of its MR-guided adaptive radiotherapy platform. Unity Pro is designed to help make adaptive radiotherapy faster, more practical and more accessible through AI-assisted contouring, GPU-accelerated planning and remote collaboration capabilities. Built to address the realities of modern clinical practice, Unity Pro simplifies workflow complexity, accelerates online adaptation and enables specialist expertise to join the workflow remotely when needed, helping more centers make daily adaptive radiotherapy practical for more patients.

# # #

Prompts

Elekta (ticker EKTA-B), listed in Sweden.

ETFs Holding Elekta

ETF Weight in ETF Shares Market value As of
DFIS 0.11% 1,009,566 $ 6.207M Nov 12, 2026
AVDS 0.10% 60,500 $ 376.196K Nov 16, 2026
DISV 0.07% 603,505 $ 3.711M Nov 12, 2026
AVDV 0.03% 878,711 $ 5.464M Nov 16, 2026
DFIC 0.02% 567,351 $ 3.488M Nov 12, 2026
DXIV 0.02% 8,634 $ 53.087K Nov 12, 2026
AVSD 0.02% 11,497 $ 71.49K Nov 16, 2026
DFAX 0.02% 342,383 $ 2.105M Nov 12, 2026
DFSI 0.01% 28,795 $ 177.049K Nov 12, 2026
DFAI 0.01% 324,504 $ 1.995M Nov 12, 2026
AVDE 0.00% 135,909 $ 845.099K Nov 16, 2026
AVIV 0.00% 1,732 $ 10.77K Nov 16, 2026